Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25374800 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP1A2TSHRHTTKMT2A | |
| SCHEMBL24761958 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP1A2TSHRHTTKMT2A | |
| SCHEMBL1665793 | 0.83 | ALDH1A1 (0.53) | ALDH1A1CYP1A2TSHRHTTKMT2A | |
| SCHEMBL1665948 | 0.83 | ALDH1A1 (0.53) | ALDH1A1CYP1A2TSHRHTTKMT2A | |
| SCHEMBL30111358 | 0.83 | ALDH1A1 (0.53) | ALDH1A1CYP1A2TSHRHTTKMT2A | |
| SCHEMBL10178099 | 0.83 | ALDH1A1 (0.53) | ALDH1A1CYP1A2TSHRHTTKMT2A | |
| SCHEMBL809782 | 0.79 | ALDH1A1 (0.49) | ALDH1A1CYP1A2TSHRHTTKMT2A | |
| SCHEMBL812944 | 0.79 | ALDH1A1 (0.49) | ALDH1A1CYP1A2TSHRHTTKMT2A | |
| SCHEMBL15539877 | 0.78 | CYP1A2 (0.53) | ALDH1A1CYP1A2TSHRHTTKMT2A | |
| SCHEMBL28369041 | 0.78 | CYP1A2 (0.53) | ALDH1A1CYP1A2TSHRHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4482856-A1 | ACTIVATABLE IL-18 POLYPEPTIDES | Bright Peak Therapeutics AG (CH) | 2025-01-01 | — | — | EP | disclosed |
| EP-4482531-A1 | IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF | Bright Peak Therapeutics AG (CH) | 2025-01-01 | — | — | EP | disclosed |
| EP-4482857-A1 | MODIFIED IL-18 POLYPEPTIDES | Bright Peak Therapeutics AG (CH) | 2025-01-01 | — | — | EP | disclosed |
| US-20240424127-A1 | IL-7 POLYPEPTIDES, IMMUNOCYTOKINES COMPRISING SAME, AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2024-12-26 | — | — | US | disclosed |
| CN-119072488-A | Activatable IL-18 polypeptides | 明峰治疗股份公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-119053347-A | Immune antigen specific IL-18 immunocytokine and uses thereof | 明峰治疗股份公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-119013289-A | Modified IL-18 polypeptides | 明峰治疗股份公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024150158-A1 | IL-7 POLYPEPTIDES, IMMUNOCYTOKINES COMPRISING SAME, AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2024-07-18 | — | — | WO | disclosed |
| EP-4366780-A1 | SYNTHETIC IL-7 AND IL-7 IMMUNOCYTOKINES | Bright Peak Therapeutics AG (CH) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023161854-A1 | IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023161853-A1 | ACTIVATABLE IL-18 POLYPEPTIDES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023161856-A1 | MODIFIED IL-18 POLYPEPTIDES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023281484-A1 | SYNTHETIC IL-7 AND IL-7 IMMUNOCYTOKINES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424127-A1 | IL-7 POLYPEPTIDES, IMMUNOCYTOKINES COMPRISING SAME, AND USES THEREOF | CD274, IL2, PDCD1 | ALDH1A1 1167/4885CYP1A2 4817/4885TSHR 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.